Stock Research: Xeris Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Xeris Pharmaceuticals

NasdaqGS:XERS US98422E1038
50
  • Value
    6
  • Growth
    91
  • Safety
    Safety
    31
  • Combined
    25
  • Sentiment
    80
  • 360° View
    360° View
    50
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing products across a range of therapies. It operates in the biopharmaceutical industry, with main businesses in commercially available products like Recorlev, Gvoke, and Keveyis, and a pipeline of development programs. The description does not specify regions of operation. In the last fiscal year, the company had a market cap of $844 million, profits of $166 million, revenue of $203 million, and 394 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 50 (better than 50% compared with alternatives), overall professional sentiment and financial characteristics for the stock Xeris Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Xeris Pharmaceuticals. The consolidated Growth Rank has a good rank of 91, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 91% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 80, which means that professional investors are more optimistic about the stock than for 80% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 31, which means that the share price of Xeris Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 69% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 6, which means that the company has a financing structure that is riskier than those of 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
31 63 21 75
Growth
91 79 65 59
Safety
Safety
6 11 18 11
Sentiment
80 68 56 22
360° View
360° View
50 55 25 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 100 92 85
Opinions Change
82 36 50 50
Pro Holdings
n/a 57 31 10
Market Pulse
46 47 27 22
Sentiment
80 68 56 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
31 63 21 75
Growth
91 79 65 59
Safety Safety
6 11 18 11
Combined
25 50 9 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
12 24 24 24
Price vs. Earnings (P/E)
36 43 67 56
Price vs. Book (P/B)
97 97 1 100
Dividend Yield
1 1 1 1
Value
31 63 21 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
80 78 76 97
Profit Growth
88 34 63 32
Capital Growth
8 81 10 70
Stock Returns
99 75 87 17
Growth
91 79 65 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
3 5 9 21
Refinancing
33 32 55 57
Liquidity
34 31 29 13
Safety Safety
6 11 18 11

Similar Stocks

Discover high‑ranked alternatives to Xeris Pharmaceuticals and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.